The mission of the Case CCC Gene Expression &Genotyping Facility (GEGF) is to facilitate implementation of high throughput genetic technologies for the research conducted by members of the CWRU community. The GEGF serves as a technical and consulting resource for Cancer Center members, as well as other investigators laboratories at CWRU, UH, CCF, MHMC and the VAMC, in the areas of high throughput expression analysis and genotyping. It is the only facility of its capability in Cleveland. This Facility utilizes Affymetrix and Applied Biosystems (ABI) technologies as well as Next Generation Sequencing (NGS) to provide global and quantitative (on user-identified genes) gene expression analysis services. While the comprehensive and quantitative properties of NGS assays, for both RNA and DNA, now make these technologies an excellent choice for many genomic studies, these approaches are still very expensive and require extensive informatics expertise for generation of useful data. Therefore, the demand for microarray technology and real time PCR to identify global changes in gene expression and genetic variants in populations has remained at undiminished levels over the past several years. Microarrays have the distinct advantage of providing economical, rapid and readily accessible data that is generically comprehensive in scope, without an overwhelming requirement for computer capacity or informatics expertise. An important service provided by the GEGF, however, is provision of advice to individual investigators on the comparative limits and applicability of the broad range of available technologies for assessment of gene expression and genomic applications. Approximately 60 investigators use the GEGF every year and 30-50% of these are first time users, documenting that the GEGF continues to enjoy a healthy level of growth and a robust level of sustained work with repeat users. Since the last competitive renewal, the Core has provided services for 71 different Cancer Center Members, distributed in all 8 of the Scientific Programs. Part of the impact is through generation of preliminary data and grant support (letters of support;sections of grants;sections for manuscripts;slides for presentations), and the GEGF has played an important role in: determining in vivo targets of the 15-PGDH colon cancer tumor suppressor pathway;identifying CAN genes (Candidate Cancer Genes) in colon cancer;and determining a candidate list of genes involved in conferring resistance or sensitivity to hepatocellular carcinoma in mice fed a high fat diet.

Public Health Relevance

The Case Comprehensive Cancer Center is Northeast Ohio's only NCI designated comprehensive cancer center providing bench-to-bedside medical research involving partnerships between basic, clinical and population scientists to speed translation of laboratory discoveries into new prevention/intervention and cancer treatments.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee B - Comprehensiveness (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Case Western Reserve University
United States
Zip Code
Burger, Denis R; Parker, Yvonne; Guinta, Kathryn et al. (2018) PRO 140 Monoclonal Antibody to CCR5 Prevents Acute Xenogeneic Graft-versus-Host Disease in NOD-scid IL-2Rynull Mice. Biol Blood Marrow Transplant 24:260-266
Anderson, Christian E; Wang, Charlie Y; Gu, Yuning et al. (2018) Regularly incremented phase encoding - MR fingerprinting (RIPE-MRF) for enhanced motion artifact suppression in preclinical cartesian MR fingerprinting. Magn Reson Med 79:2176-2182
Shi, Xiaojun; Wang, Bingcheng (2018) Caught in the ""Akt"": Cross-talk between EphA2 and EGFR through the Akt-PIKfyve axis maintains cellular sensitivity to EGF. Sci Signal 11:
Tartakoff, Alan Michael; Dulce, David; Landis, Elizabeth (2018) Delayed Encounter of Parental Genomes Can Lead to Aneuploidy in Saccharomyces cerevisiae. Genetics 208:139-151
Gromovsky, Anthony D; Schugar, Rebecca C; Brown, Amanda L et al. (2018) ?-5 Fatty Acid Desaturase FADS1 Impacts Metabolic Disease by Balancing Proinflammatory and Proresolving Lipid Mediators. Arterioscler Thromb Vasc Biol 38:218-231
Ignatz-Hoover, James J; Wang, Victoria; Mackowski, Nathan M et al. (2018) Aberrant GSK3? nuclear localization promotes AML growth and drug resistance. Blood Adv 2:2890-2903
Hubler, Zita; Allimuthu, Dharmaraja; Bederman, Ilya et al. (2018) Accumulation of 8,9-unsaturated sterols drives oligodendrocyte formation and remyelination. Nature 560:372-376
Asthana, Abhishek; Ramakrishnan, Parameswaran; Vicioso, Yorleny et al. (2018) Hexosamine Biosynthetic Pathway Inhibition Leads to AML Cell Differentiation and Cell Death. Mol Cancer Ther 17:2226-2237
Belur Nagaraj, Anil; Kovalenko, Olga; Avelar, Rita et al. (2018) Mitotic Exit Dysfunction through the Deregulation of APC/C Characterizes Cisplatin-Resistant State in Epithelial Ovarian Cancer. Clin Cancer Res 24:4588-4601
Yang, Xiaosong; Pan, You; Qiu, Zhaojun et al. (2018) RNF126 as a Biomarker of a Poor Prognosis in Invasive Breast Cancer and CHEK1 Inhibitor Efficacy in Breast Cancer Cells. Clin Cancer Res 24:1629-1643

Showing the most recent 10 out of 1227 publications